Single Dilation in Primary Inflatable Penile Prosthesis Placement Is Associated With Fewer Corporal Complications Than Sequential Dilation.

Objective: To assess the difference in outcomes between single dilation (SingD) and sequential dilation (SeqD) in primary penile implantation, hypothesizing that patients who undergo SeqD had higher rates of noninfectious complications.
Methods: We performed a multicenter, retrospective study of men undergoing primary inflatable penile prosthesis placement. Intraoperative complications and postoperative noninfectious outcomes were assessed between the two groups. Multivariable analysis was performed to identify predictors of complications.
Results: A total of 3293 patients met inclusion criteria. After matching, there were 379 patients who underwent SingD and 379 patients who underwent SeqD. There was no significant difference in intraoperative complications between patients who underwent SingD vs SeqD, nor was there any difference in cylinder length (20 cm with interquartile range [IQR] 18-21 cm vs 20 cm with IQR 18-20 cm respectively, P = .4). On multivariable analysis, SeqD (OR 5.23 with IQR 2.74-10, P < .001) and older age (OR 1.04 with IQR 1.01-1.06, P = .007) were predictive of postoperative noninfectious complications. There was no significant difference in intraoperative complications between patients who underwent SingD vs SeqD, nor was there any difference in cylinder length. SeqD and older age were predictive of postoperative noninfectious complications.
Conclusion: During inflatable penile prosthesis placement in the uncomplicated patient without fibrosis, SingD is a safe technique to utilize during implantation that will minimize postoperative adverse events, and promote device longevity without loss of cylinder length.
Competing Interests: Declaration of Competing Interest Martin S. Gross, consultant for Coloplast. Daniar Osmonov, consultant for Coloplast, Intuitive Surgical, Fidelis. Aaron Lentz, speaker, consultant, preceptor for Coloplast and Boston Scientific. Paul Perito, consultant for Coloplast, Boston Scientific, Urofill. Matthew Ziegelmann, consultant for Endo Pharma. Faysal A. Yafi, consultant for Coloplast, Cynosure, Antares Pharma, Clarus Pharmaceuticals, Acerus Pharma. Jay Simhan, consultant for Boston Scientific, Coloplast. The other authors have no conflict of interest to declare.
(Copyright © 2023 Elsevier Inc. All rights reserved.)